HELP — Helus Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1833141 ·
Ontario, Canada
Last close
$7.20
Market Cap
$526.03M
52W High
$15.15
52W Low
$3.76
ADV30
1,910,236
Next earnings
2027-02-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -104,519,000 | -103,091,000 | 263,199,000 | 171,071,000 | 18,812,000 |
| Jun 2026 | 0 | — | -49,082,000 | -47,819,000 | 259,655,000 | 166,365,000 | 17,568,000 |
| Mar 2026 | 0 | — | -47,859,000 | -46,995,000 | 251,166,000 | 157,258,000 | 19,377,000 |
| Dec 2025 | 0 | — | -41,210,000 | -42,668,000 | 290,112,000 | 195,128,000 | 16,178,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-140,793,000
Investing CF
$-1,462,000
Financing CF
$190,139,000
CapEx
$-1,462,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.40
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-437,354,000
Inventory
—
Receivables
$5,038,000
ST Investments
—
EBIT TTM
$-167,045,000
Pretax Income TTM
$-171,204,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -142,587,000 | -147,998,000 | 251,166,000 | 19,377,000 | 231,789,000 | -133,271,000 |
| Mar 2025 | 0 | -103,125,000 | -81,607,000 | 179,897,000 | 14,900,000 | 164,997,000 | -72,328,000 |
| Mar 2024 | 0 | -78,836,000 | -78,080,000 | 302,023,000 | 10,096,000 | 291,927,000 | -68,908,000 |
| Mar 2023 | 0 | -51,518,000 | -47,490,000 | 53,897,000 | 5,663,000 | 48,234,000 | -47,431,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.83
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $6.00 · spot: $6.89 · call volume: 1,114 · put volume: 1,037
Expected Move to 2027-01-15:
±$3.40
(49.35%) —
implied range
$3.49 –
$10.29
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVO | Evotec SE | $525.98M | $1.48 | — |
| ACRS | Aclaris Therapeutics, Inc. | $536.11M | $3.38 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $507.20M | $13.04 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
News headlines (Yahoo Finance, 1h cache)
Helus Pharma (HLP) Stock Fair Value Rises After HLP003 Phase 3 Analyst Revisions
2026-11-18 08:12 · Yahoo
HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data
2026-11-16 20:52 · Yahoo
Why Is HELP Stock Rising Today?
2026-11-16 13:50 · Yahoo
Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint
2026-11-16 13:34 · Yahoo
Helus Pharma stock tumbles 21% despite positive trial results
2026-11-16 13:07 · Yahoo
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
2026-11-16 12:00 · Yahoo
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
2026-11-16 11:00 · Yahoo
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
2026-11-15 17:00 · Yahoo
Is Helus Pharma (HELP) Trading At A Premium To Book Value?
2026-11-11 02:16 · Yahoo
Cybin Expects Key Phase III Depression Trial Results This Quarter
2026-11-10 05:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.